NEA Management Company
TIMONIUM, MDfiles as NEA Management Company, LLC
$1.6bn in 26 US stocks at the end of 30 June 2026. The top 10 are 89.8% of the money. It changed about 24.7% of the portfolio this quarter.
Value
$1.6bn
Stocks
26
Top 10 share
89.8%
Turnover
24.7%
What changed this quarter
New
Bought for the first time this quarter.
- Karyopharm TherapeuticsKPTI0.4% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- CelcuityCELC11.3% of the fund-25%
- CVRxCVRX0.6% of the fund-4%
Sold out
Sold their entire stake.
- Arcellx-100%
Holdings
- Senti Biosciences
- Share
- 0.3%
- Value
- $4m
- Shares
- 3,775,615
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Trevi TherapeuticsTRVI | 15.5% | $247m | 13,222,228 | Held |
| MBX BiosciencesMBX | 12.6% | $200m | 3,614,486 | Held |
| Monte Rosa TherapeuticsGLUE | 11.7% | $186m | 7,692,298 | Held |
| CelcuityCELC | 11.3% | $179m | 1,710,561 | -25% |
| SpyGlass PharmaSGP | 10.4% | $165m | 7,392,301 | Held |
| SavaraSVRA | 9.5% | $151m | 24,471,264 | Held |
| Zenas BioPharmaZBIO | 6.4% | $102m | 4,023,219 | Held |
| CourseraCOUR | 4.6% | $73m | 12,867,769 | Held |
| Aurinia PharmaceuticalsAUPH | 4.2% | $67m | 3,969,834 | Held |
| CRISPR Therapeutics AGCRSP | 3.6% | $58m | 1,058,570 | Held |
| Oric PharmaceuticalsORIC | 2.8% | $45m | 4,118,621 | Held |
| Phathom PharmaceuticalsPHAT | 1.3% | $21m | 1,960,169 | Held |
| Korro BioKRRO | 1.1% | $17m | 1,297,893 | Held |
| X4 PharmaceuticalsXFOR | 1.0% | $15m | 3,233,743 | Held |
| Champions OncologyCSBR | 0.7% | $11m | 1,713,720 | Held |
| NkartaNKTX | 0.6% | $10m | 3,568,781 | Held |
| CVRxCVRX | 0.6% | $10m | 1,954,440 | -4% |
| Black Diamond TherapeuticsBDTX | 0.5% | $8m | 4,448,757 | Held |
| Karyopharm TherapeuticsKPTI | 0.4% | $6m | 576,780 | New |
| InventivaIVA | 0.3% | $6m | 1,462,586 | Held |
| LeonaBioLONA | 0.3% | $4m | 464,398 | Held |
| Senti Biosciences | 0.3% | $4m | 3,775,615 | Held |
| Marker TherapeuticsMRKR | 0.2% | $2m | 1,625,678 | Held |
| OnKure TherapeuticsOKUR | 0.1% | $2m | 478,548 | Held |
| ImageneBioIMA | <0.1% | $295,030 | 50,005 | Held |
| Gossamer BioGOSS | <0.1% | $164,600 | 1,000,000 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 19.5% since 30 June 2025.
Where the money is
Health care95.2%
Technology4.6%
Other0.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.